Your session is about to expire
← Back to Search
Drug Coated Balloon
Drug-Coated Balloon for Arteriovenous Fistula (AVPAS Trial)
N/A
Recruiting
Led By Scott Trerotola, MD
Research Sponsored by C. R. Bard
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Target lesion must be a mature arteriovenous fistula located in the arm presenting with any clinical, physiological or hemodynamic abnormalities warranting angiographic imaging as defined in the K/DOQI guidelines
Subject has a target lesion that can be treated with available LUTONIX DCB according to the Instructions For Use (IFU)
Must not have
Target lesion is located central to the axillosubclavian junction
A thrombosed access or an access with a thrombosis treated ≤7 days before to the index procedure
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6, 12, 18, 24 months
Awards & highlights
No Placebo-Only Group
Summary
This trial investigates a special balloon coated with medication to help open and keep open blood vessels in the arms of patients with problematic AV fistulae, which are crucial for dialysis. The Selution Sustained Limus Release (SLR) sirolimus-coated balloon is being tested for improving the patency of failing arteriovenous fistulas (AVF) in hemodialysis patients.
Who is the study for?
This trial is for adults over 18 with a mature arteriovenous fistula in the arm that needs treatment based on specific guidelines. Participants must be able to give informed consent and follow the study's visit schedule. They can't join if they have other conditions affecting data or life expectancy, recent surgeries at the site, stents in place, are in another study, have severe contrast allergies, or had a thrombosis treated recently.
What is being tested?
The Lutonix® 035 AV Drug Coated Balloon (DCB) PTA Catheter is being tested for safety and effectiveness in treating dysfunctional arteriovenous fistulas located in the upper extremity. This global study involves one group of participants who will all receive this particular treatment following successful pre-dilation of their lesion.
What are the potential side effects?
Possible side effects may include reactions related to balloon angioplasty such as pain at the access site, bleeding or bruising, blood vessel damage, infection risk at the catheter insertion point and potential allergic reactions to materials used.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My arm's blood vessel connection needs imaging due to issues.
Select...
My lesion can be treated with a specific device according to its usage guide.
Select...
I am an adult over 18 and not pregnant or breastfeeding.
Select...
My AV fistula has a narrowing in the vein from where it's connected to near my shoulder.
Select...
My artery was successfully widened without major issues using a special balloon.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
My target lesion is near the center of my shoulder area.
Select...
I had a clot in my dialysis access treated within the last week.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6, 12, 18, 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6, 12, 18, 24 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Percentage of Participants With No Primary Safety Events
Percentage of Participants With Target Lesion Primary Patency (TLPP)
Secondary study objectives
Number of re-interventions required to maintain access circuit patency
Number of re-interventions required to maintain target lesion patency
Percentage of Participants With Abandonment of Permanent Access in the Index Extremity
+7 moreOther study objectives
Vital status of participants
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: LUTONIX 035 Drug Coated Balloon PTA CatheterExperimental Treatment1 Intervention
This is a single-arm study. All subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for arteriovenous fistulae (AVF) include percutaneous transluminal angioplasty (PTA) and the use of drug-coated balloons (DCBs). PTA mechanically dilates the vessel to improve blood flow, while DCBs, such as the Lutonix® 035 AV DCB, release antiproliferative drugs like paclitaxel to prevent restenosis by inhibiting smooth muscle cell proliferation.
This is crucial for AVF patients as it helps maintain the patency of the fistula, ensuring effective dialysis access and reducing the need for repeat interventions.
The guglielmi detachable coil in the treatment of arteriovenous fistulae.
The guglielmi detachable coil in the treatment of arteriovenous fistulae.
Find a Location
Who is running the clinical trial?
C. R. BardLead Sponsor
106 Previous Clinical Trials
39,744 Total Patients Enrolled
6 Trials studying Arteriovenous Fistula
999 Patients Enrolled for Arteriovenous Fistula
Scott Trerotola, MDPrincipal InvestigatorHospital of the University of Pennsylvania; Division of Interventional Radiology
1 Previous Clinical Trials
285 Total Patients Enrolled
1 Trials studying Arteriovenous Fistula
285 Patients Enrolled for Arteriovenous Fistula
Dheeraj Rajan, MDPrincipal InvestigatorUniversity Health Network; Division of Vascular & Interventional Radiology
3 Previous Clinical Trials
537 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I haven't had surgery at the procedure site in the last 30 days.My arm's blood vessel connection needs imaging due to issues.My lesion can be treated with a specific device according to its usage guide.I am an adult over 18 and not pregnant or breastfeeding.You have an allergy to contrast dye that cannot be controlled.My target lesion is near the center of my shoulder area.The area being studied is inside a metal stent.I had a clot in my dialysis access treated within the last week.My AV fistula has a narrowing in the vein from where it's connected to near my shoulder.My artery was successfully widened without major issues using a special balloon.
Research Study Groups:
This trial has the following groups:- Group 1: LUTONIX 035 Drug Coated Balloon PTA Catheter
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.